Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret
Copenhagen, Region H, 2100, Denmark
NCT Number: NCT04897750
This is a prospective non-randomized, open-label, single dose (and a second dose if needed), PK study in 25 children age 1-17 years. The proposed number of study participants by subset is: 8 paediatric participants 1-2 years; 8 paediatric participants >2-6 years and 9 paediatric participants >6-17 years.
Looking for future studies?
Notify Me1 year–17 year
All sexes
Interventional
Phase 2
Copenhagen, Region H, 2100, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
Time frame: 0 - 120 minutes
Area under the concentration vs time curve
Time frame: 0 - 120 minutes
Peak concentration (Cmax)
Time frame: 120 - 240 minutes
Volumen of distribution (Vd)
Time frame: 120 - 240 minutes
Half life (T½)
Time frame: 120 - 240 minutes
Clearance,
Time frame: 0 - 1 hour
pain intensity by age-appropriate scale in relation to the placement of peripheral venous catheter
Time frame: 0 - 1 hour
Assessment of sedation at the time of placement of the peripheral venous catheter using the University of Michigan Sedation Score
Time frame: 0- 4 hours
Acceptance of the intranasal route of administration by the child, assessed by the child or legally acceptable representative or health care provider.
Cessatech A/S
Industry
Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05999734
Agnosia, Analgesia
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT02471898
Agnosia, Analgesia
Pasadena, California, United States
View Trial DetailsNCT06675916
Agnosia, Analgesia
Villeurbanne, France
View Trial DetailsNCT05250492
Agnosia, Analgesia
Lanester, France
View Trial Details